Assessing Tumour Localized 4-1BB Stimulation for Cancer Immunotherapy

Time: 9:30 am
day: Day One


  • Overcoming 1st generation 4-1BB agonist safety and efficacy drawbacks with a 4-1BB/PD-L1 bispecific Anticalin® protein/mAb fusion protein
  • Harnessing 4-1BB localized activity in the TME, while also offering the benefit of checkpoint inhibition
  • Preclinical data package to guide clinical study